Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, today announced the successful completion of the squeeze-out merger under Swiss law (the “Squeeze-Out Merger”) pursuant to which VectivBio Holding AG (“VectivBio”) has been merged with and into Ironwood Pharmaceuticals GmbH (“Merger Sub”), a wholly-owned subsidiary of Ironwood organized under the laws of Switzerland. As a result of the Squeeze-Out Merger, all remaining outstanding ordinary shares of VectivBio not previously purchased by Ironwood have been cancelled and converted into the right to receive $17.00 per share in cash, subject to any applicable withholding taxes. The Squeeze-Out Merger was approved by shareholders of VectivBio at the extraordinary general meeting held on November 28, 2023.

As previously announced, Ironwood successfully completed a tender offer on June 29, 2023 to purchase an aggregate of approximately 97.5 percent of the outstanding Shares (the “Tender Offer”). Ironwood accepted for payment and promptly paid for all such Shares that were validly tendered and not validly withdrawn in accordance with the terms of the Tender Offer Statement on Schedule TO filed with the U.S. Securities and Exchange Commission on May 31, 2023, as amended. Following the Tender Offer, Ironwood caused VectivBio to voluntarily delist its shares from Nasdaq.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD), an S&P SmallCap 600® company, is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). In June 2023, the U.S. Food and Drug Administration also approved LINZESS for the treatment of functional constipation in pediatric patients ages 6-17 years-old. Ironwood is also advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF) as well as several earlier stage assets. Building upon our history of GI innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs.

Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, and has additional operations in Basel, Switzerland.

We routinely post information that may be important to investors on our website at www.ironwoodpharma.com. In addition, follow us on X and on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231212626621/en/